返回 Agenda
Session 4: Cross Industry Consortia Addressing RWE: Impact and Future Directions
Session Chair(s)
David Martin, MD, MPH
Vice President, Global Head RWE
Moderna, United States
Sulabha Ramchandran, PhD, MS
Vice President and Head, US and Regions, Value Evidence and Outcomes
GlaxoSmithKline, United States
This session will bring together leaders from cross-industry consortia to discuss key strategic objectives for RWE. Speakers will address existing RWE initiative priorities, deliverables to date, key learnings, and the manner in which they are shaping future priorities. Participants will be exposed to resources for best practices, assess opportunities to engage, consider applications within biopharmaceutical development.
Learning Objective : At the conclusion of this session, participants should be able to:
- Gain awareness of the strategic goals and foci of cross-industry RWE initiatives
- Identify key learnings and deliverables generated to date
- Apply key resources for best practices and assess opportunities to engage
Speaker(s)
PhRMA and Bio RWE Initiatives
Rebecca Lipsitz, PhD
AstraZeneca, United States
Senior Director, TA Regulatory Intelligence and Portfolio Policy, Late R&I RA
Transcelerate RWE Workstreams
Cathy W Critchlow, PhD, MSc
Amgen, Inc, United States
Vice President, R&D Data Strategy
Learnings from OPERAND
William H. Crown, PhD, MA
Brandeis University , United States
Distinguished Research Scientist, Heller School for Social Policy and Management
Overview of Duke Margolis RWE Initiatives
Morgan Romine, MPA
Duke University, United States
Chief of Staff
FOCR Oncology RWE Validation and Endpoints
Jeff Allen, PhD
Friends of Cancer Research, United States
President and Chief Executive Officer